Onset of subacute cutaneous lupus erythematosus after the initiation of immune checkpoint inhibitor therapy of cancer

Ogawa-Momohara M Muro Y Goto K , et al. Subacute cutaneous lupus erythematosus with melanocyte elimination induced by pembrolizumab. J Dermatol 2020; 47: e217–e219.

Blakeway EA Elshimy N Muinonen-Martin A Marples M Mathew B Mitra A. Cutaneous lupus associated with pembrolizumab therapy for advanced melanoma: a report of three cases. Melanoma Res 2019; 29: 338–341.

Zitouni NB Arnault JP Dadban A Attencourt C Lok CC Chaby G. Subacute cutaneous lupus erythematosus induced by nivolumab: two case reports and a literature review. Melanoma Res 2019; 29: 212–215.

Liu RC Sebaratnam DF Jackett L Kao S Lowe PM. Subacute cutaneous lupus erythematosus induced by nivolumab. Australas J Dermatol 2018; 59: e152–e154.

Kosche C Owen JL Choi JN. Widespread subacute cutaneous lupus erythematosus in a patient receiving checkpoint inhibitor immunotherapy with ipilimumab and nivolumab. Dermatol Online J 2019; 25: 13030.

Michot JM Fusellier M Champiat S , et al. Drug-induced lupus erythematosus following immunotherapy with anti-programmed death-(ligand) 1. Ann Rheum Dis 2019; 78: e67.

Jatwani S abd Hearth Holmes MP. Subacute cutaneous lupus erythematosus. Treasure Island, FL: StatPearls Publishing, 2020.

Laurinaviciene R Sandholdt LH Bygum A. Drug-induced cutaneous lupus erythematosus: 88 new cases. Eur J Dermatol 2017; 27: 28–33.

Muntyanu A, Netchiporouk E, Gerstein W, Gniadecki R and Litvinov IV. Cutaneous Immune-Related adverse events (irAEs) to immune checkpoint inhibitors: a dermatology perspective on management. J Cutan Med Surg. Epub ahead of print August 2020. DOI: 10.1177/1203475420943260.

González García A Sifuentes Giraldo WA Grillo Fernández E Zea Mendoza A. Subacute cutaneous lupus erythematosus associated with pemetrexed plus carboplatin chemotherapy. J Clin Rheumatol 2014; 20: 449–450.